Lercanidipine Accord

Lercanidipine, the active ingredient in Lercanidipine Accord, is a calcium channel blocker presented as an oral tablet for oral use. It is used to treat hypertension in adult patients requiring blood pressure control. GNH USA supplies Lercanidipine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension and related blood‑pressure disorders. - Hypertension: lowers elevated systolic and diastolic blood pressure to target levels. - Essential hypertension: provides sustained blood‑pressure control in primary hypertension. - Severe hypertension: assists in achieving rapid reduction of markedly high blood pressure when combined with other antihypertensives.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation and reddening of skin. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Tachycardia: increased heart rate. - Palpitations: awareness of heartbeat.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Myocardial infarction: rare occurrence of heart attack. - Cardiac arrhythmias: abnormal heart rhythms. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Angio‑edema: swelling of face, lips, or throat.

Before initiating therapy with Lercanidipine, several safety considerations should be observed. - Blood pressure monitoring: assess baseline and follow‑up readings to avoid excessive hypotension. - Hepatic function: evaluate liver enzymes in patients with known hepatic impairment. - Elderly patients: start at the lowest effective dose and monitor for dizziness. - Concomitant antihypertensives: adjust doses to prevent additive blood‑pressure lowering effects. - Heart failure: use with caution and monitor for worsening symptoms. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations. - Concomitant use with other potent antihypertensives: risk of severe hypotension. - Grapefruit juice: can elevate drug levels leading to adverse effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin): may reduce therapeutic effect. - Diuretics: may enhance orthostatic hypotension. - Beta‑blockers: monitor for additive heart‑rate reduction. - NSAIDs: may blunt antihypertensive response.